R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
R&D Parkinson’s disease: Transitioning from symptom control to d... The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
R&D Sponsored 12 Questions with Lucy Walker Lucy Walker is the Head of Medical Operations at the growing medical consultancy LUCENT Biopharma. Find out more in a new 12 Questions With.
R&D LSX2026: Non-opioid pain relief and pharma positivity, with ... Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
